Skip to content

MapLight Therapeutics, Inc. MPLT Total Current Liabilities

Total Current Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$19.16B-20.4%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$57.72B+1.4%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$831.7M+59.1%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$305.52M+1.0%
AbbVie logo
AbbVieABBV
$42.1B+15.6%
LBR
LB Pharmaceuticals Inc Common StockLBRX
$10.91M

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B+100%
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's total current liabilities?
MapLight Therapeutics, Inc. (MPLT) reported total current liabilities of $14.28M in Q1 2026.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.